


Molecule of the Month

ICE0924



This month's molecule of the month is ICE0924 developed by Imperial College London. ICE0924 is an orally bioavailable selective inhibitor of Cyclin-dependent kinase (CDK)7 for Cancer Treatment. Cyclin-dependent kinase (CDK)7 is required for transcription, and range of cancer types are sensitive to CDK7 inhibition. ICE0924 selectively inhibits CDK7 in preference over other cyclin-dependent kinases. ICE0924 was licenced to Carrick Therapeutics, who renamed it CT7001, and is currently undergoing phase I clinical trials.

